https://www.selleckchem.com/JAK.html
75; 95% CI 0.08 to 7.40, p= 0.81). There was no difference of the ICH rate between two groups (adjusted odds ratio 0.44; 95% CI 0.13 to 1.48, p= 0.18). In the inverse probability of treatment weighting-propensity score-adjusted cohort, similar differences were found for functional and safety outcomes. Our study suggested that tirofiban use appears to be safe as monotherapy in AIS treatment compared with common dual antiplatelet therapy, however, no improvement in functional outcomes was found. Chinese clinical trial registry, ChiCTR2000034443 , 05/0
Like
Comment
Share
